Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company leveraging advanced genetic research to develop transformative medicines, particularly for diabetes and related conditions.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases.
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), ...
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: “LX9211 - Changing the Paradigm for Treatment of Neuropathic Pain.” The event will be ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lexicon Pharmaceuticals (LXRX – Research Report) and Allakos (ALLK – Research Report). Lexicon Pharmaceuticals ...
Lexicon Pharmaceuticals ... a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The ...